285 related articles for article (PubMed ID: 8390806)
1. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease.
Holthoff VA; Koeppe RA; Frey KA; Penney JB; Markel DS; Kuhl DE; Young AB
Ann Neurol; 1993 Jul; 34(1):76-81. PubMed ID: 8390806
[TBL] [Abstract][Full Text] [Related]
2. Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography.
Künig G; Leenders KL; Sanchez-Pernaute R; Antonini A; Vontobel P; Verhagen A; Günther I
Ann Neurol; 2000 May; 47(5):644-8. PubMed ID: 10805336
[TBL] [Abstract][Full Text] [Related]
3. Benzodiazepine receptor quantification in Huntington's disease with [(123)I]omazenil and SPECT.
Pinborg LH; Videbaek C; Hasselbalch SG; Sørensen SA; Wagner A; Paulson OB; Knudsen GM
J Neurol Neurosurg Psychiatry; 2001 May; 70(5):657-61. PubMed ID: 11309461
[TBL] [Abstract][Full Text] [Related]
4. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.
Young AB; Penney JB; Starosta-Rubinstein S; Markel DS; Berent S; Giordani B; Ehrenkaufer R; Jewett D; Hichwa R
Ann Neurol; 1986 Sep; 20(3):296-303. PubMed ID: 2945510
[TBL] [Abstract][Full Text] [Related]
5. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function.
Berent S; Giordani B; Lehtinen S; Markel D; Penney JB; Buchtel HA; Starosta-Rubinstein S; Hichwa R; Young AB
Ann Neurol; 1988 Jun; 23(6):541-6. PubMed ID: 2970247
[TBL] [Abstract][Full Text] [Related]
7. Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography.
Koeppe RA; Holthoff VA; Frey KA; Kilbourn MR; Kuhl DE
J Cereb Blood Flow Metab; 1991 Sep; 11(5):735-44. PubMed ID: 1651944
[TBL] [Abstract][Full Text] [Related]
8. [18F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors.
Gründer G; Siessmeier T; Lange-Asschenfeldt C; Vernaleken I; Buchholz HG; Stoeter P; Drzezga A; Lüddens H; Rösch F; Bartenstein P
Eur J Nucl Med; 2001 Oct; 28(10):1463-70. PubMed ID: 11685488
[TBL] [Abstract][Full Text] [Related]
9. Regional specific binding of [11C]RO 15 1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET.
Pappata S; Samson Y; Chavoix C; Prenant C; Mazière M; Baron JC
J Cereb Blood Flow Metab; 1988 Jun; 8(3):304-13. PubMed ID: 2835381
[TBL] [Abstract][Full Text] [Related]
10. 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping.
Weeks RA; Cunningham VJ; Piccini P; Waters S; Harding AE; Brooks DJ
J Cereb Blood Flow Metab; 1997 Sep; 17(9):943-9. PubMed ID: 9307607
[TBL] [Abstract][Full Text] [Related]
11. Measurement of benzodiazepine receptor number and affinity in humans using tracer kinetic modeling, positron emission tomography, and [11C]flumazenil.
Price JC; Mayberg HS; Dannals RF; Wilson AA; Ravert HT; Sadzot B; Rattner Z; Kimball A; Feldman MA; Frost JJ
J Cereb Blood Flow Metab; 1993 Jul; 13(4):656-67. PubMed ID: 8391018
[TBL] [Abstract][Full Text] [Related]
12. Neurotransmitter receptor alterations in Huntington's disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes.
Whitehouse PJ; Trifiletti RR; Jones BE; Folstein S; Price DL; Snyder SH; Kuhar MJ
Ann Neurol; 1985 Aug; 18(2):202-10. PubMed ID: 2994554
[TBL] [Abstract][Full Text] [Related]
13. Altered GABAA receptor density and unaltered blood-brain barrier transport in a kainate model of epilepsy: an in vivo study using 11C-flumazenil and PET.
Syvänen S; Labots M; Tagawa Y; Eriksson J; Windhorst AD; Lammertsma AA; de Lange EC; Voskuyl RA
J Nucl Med; 2012 Dec; 53(12):1974-83. PubMed ID: 23143088
[TBL] [Abstract][Full Text] [Related]
14. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates.
Brandt J; Folstein SE; Wong DF; Links J; Dannals RF; McDonnell-Sill A; Starkstein S; Anders P; Strauss ME; Tune LE
J Neuropsychiatry Clin Neurosci; 1990; 2(1):20-7. PubMed ID: 1983772
[TBL] [Abstract][Full Text] [Related]
15. Quantification of benzodiazepine receptors in human brain using PET, [11C]flumazenil, and a single-experiment protocol.
Delforge J; Pappata S; Millet P; Samson Y; Bendriem B; Jobert A; Crouzel C; Syrota A
J Cereb Blood Flow Metab; 1995 Mar; 15(2):284-300. PubMed ID: 7860662
[TBL] [Abstract][Full Text] [Related]
16. Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle.
Lassen NA; Bartenstein PA; Lammertsma AA; Prevett MC; Turton DR; Luthra SK; Osman S; Bloomfield PM; Jones T; Patsalos PN
J Cereb Blood Flow Metab; 1995 Jan; 15(1):152-65. PubMed ID: 7798333
[TBL] [Abstract][Full Text] [Related]
17. Kinetic modeling of benzodiazepine receptor binding with PET and high specific activity [(11)C]Iomazenil in healthy human subjects.
Bremner JD; Horti A; Staib LH; Zea-Ponce Y; Soufer R; Charney DS; Baldwin R
Synapse; 2000 Jan; 35(1):68-77. PubMed ID: 10579810
[TBL] [Abstract][Full Text] [Related]
18. Similarity and robustness of PET and SPECT binding parameters for benzodiazepine receptors.
Millet P; Graf C; Buck A; Walder B; Westera G; Broggini C; Arigoni M; Slosman D; Bouras C; Ibáñez V
J Cereb Blood Flow Metab; 2000 Nov; 20(11):1587-603. PubMed ID: 11083234
[TBL] [Abstract][Full Text] [Related]
19. Neuroinflammation in Huntington's Disease: New Insights with
Lois C; González I; Izquierdo-García D; Zürcher NR; Wilkens P; Loggia ML; Hooker JM; Rosas HD
ACS Chem Neurosci; 2018 Nov; 9(11):2563-2571. PubMed ID: 29719953
[TBL] [Abstract][Full Text] [Related]
20. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease.
Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME
Ann Neurol; 1990 Nov; 28(5):614-21. PubMed ID: 1979723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
